Faculty & Staff at TUC

Rae Matsumoto

Rae Matsumoto

College: COP

Department: Deans Office

Title: Dean

Phone: (707) 638-5926

Fax: (707) 638-5266

E-Mail: rae.matsumoto@tu.edu

Office: Administration & Faculty 2, Rm. 121

Dr. Matsumoto is a broadly trained scientist and educator, with over 20 years of administrative experience building collaborative multidisciplinary training programs. Dr. Matsumoto obtained her Ph.D. in psychology at Brown University where her primary research interest focused on, and continues to deal with the effects of drugs on the brain. Dr. Matsumoto subsequently received post-doctoral training in biochemistry and physiology at Brown and Northwestern Universities. She then served as an Assistant Professor of Neurology at the University of California Irvine, and Co-Director of its Parkinson's and Movement Disorders Program. In this role, Dr. Matsumoto was responsible for coordinating all of the basic science research activities of the unit, including the training of clinicians, fellows and students and the development of novel translational research programs. In 1996, Dr. Matsumoto moved to the University of Oklahoma Health Sciences Center in the College of Pharmacy, where her research focused on medications development for the treatment of drug abuse. She moved up the ranks to become an Edith Gaylord Harper Presidential Professor, and also held an adjunct appointment in the Department of Psychiatry. In addition, she served as the Associate Director of the Oklahoma Center for Neuroscience, where her duties included running the graduate program, and coordinating community outreach and educational activities. In 2004, Dr. Matsumoto moved to the University of Mississippi, where she served as the founding Director of the Center for Research Excellence in Natural Products Neuroscience after leveraging the school's first COBRE grant. She joined West Virginia University in 2008 to serve as the Associate Dean for Research and Graduate Programs, a newly created position in the School of Pharmacy, where she established a new external funding baseline for the school which exceeded its previous historic high and grew the graduate program into the largest biomedical Ph.D. program at WVU. Dr. Matsumoto joined Touro University California as the Dean of the College of Pharmacy in 2014 where she continues to stimulate the training of future leaders for the profession by promoting innovation, excellence, and service.

Institution                      Degree    Field of Study                     Obtained

Creighton University        B.S.        Biology & Psychology          1985

Brown University             Sc.M.      Psychology                         1987

Brown University             Ph.D.      Psychology                         1989

Brown University             Postdoc   Psychology & Biochemistry  1989-1990

Northwestern University   Postdoc   Physiology                         1990-1992

My recent research focuses on the development of potential new drugs for the treatment of neurological and psychiatric disorders, and elucidation of cellular mechanisms through which they produce their therapeutic effects.

Psychostimulant abuse: Currently, there are no FDA-approved medications to treat cocaine and methamphetamine abuse, a void which exacerbates a major health and societal problem. Together with our medicinal chemist collaborators, we have developed new classes of drugs that exert powerful effects in mitigating the actions of psychostimulants in laboratory animals. The research in our lab is focused on optimizing these compounds, and identifying cellular and molecular mechanisms through which they produce their beneficial actions.

Opioid analgesics: Opioid analgesics such as morphine provide powerful pain relief. However, their therapeutic benefits are limited by the development of tolerance, physical dependence, and constipation. In collaboration with our medicinal chemist colleagues, novel opioid compounds are being designed, synthesized, and tested with the goal of developing effective pain relievers with reduced side effects and lower potential for abuse.

Depression: Depression affects about 20% of Americans and is the leading cause of disability in the U.S. Despite recent advances, it takes several weeks before antidepressant medications are effective and about 30% of patients still do not respond. Our research group is developing fast acting antidepressant drugs which are currently being evaluated in animals, cell-based model systems, and human clinical trials.

(Peer-reviewed from the last five years)

  1. Robson, M. J., Elliott, M., Seminerio, M. J. and Matsumoto, R. R. (2012) Evaluation of sigma receptors in the antidepressant-like effects of ketamine in vitro and in vivo. European Neuropsychopharmacology 22: 308-317. (PMID: 21911285)

  2. Kaushal, N., Elliott, M., Robson, M. J., Iyer, A. K. V., Rojanasakul, Y., Coop, A. and Matsumoto, R. R. (2012) AC927, a sigma ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. Molecular Pharmacology 81: 299-308. (PMID: 22101517)

  3. Seminerio, M. J., Robson, M. J., Abdelazeem, A. H., Mesangeau, C., Jamalapuram, S., Avery, B. A., McCurdy, C. R. and Matsumoto, R. R. (2012) Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine. AAPS Journal 14: 43-51. (PMID: 22183188)

  4. Xu, Y. T., Robson, M. J., Szeszel-Fredowicz, W., Patel, D., Rooney, R., McCurdy, C. R. and Matsumoto, R. R. (2012) CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain. Pharmacology Biochemistry and Behavior 101: 174-180. (PMID: 22234290)

  5. Robson, M. J., Noorbakhsh, B., Seminerio, M. J. and Matsumoto, R. R. (2012) Sigma-1 receptors: Potential targets for the treatment of substance abuse disorders. Current Pharmaceutical Design 18: 902-919. (PMID: 22288407)
  6. El-Alfy, A. T., Abourashed, E. and Matsumoto, R. R. (2012) Nature against depression. Current Medicinal Chemistry 19: 2229-2241. (PMID: 22414105)
  7. Stavitskaya, L., Shim, J., Healy, J. R., Matsumoto, R. R., MacKerell, A. D. Jr. and Coop, A. (2012) Deconstructing 14-phenyl propyloxymetopon: Minimal requirements for binding to mu-opioid receptors. Bioorganic and Medicinal Chemistry 20: 4556-4563. (PMID: 22677527)

  8. Turner, R. C., Seminerio, M. J., Naser, Z. J., Ford, J. N., Martin, S. J., Matsumoto, R. R., Rosen, C. L. and Huber, J. D. (2012) Effects of aging on behavioral assessment performance: implications for clinically relevant models of neurological disease. Journal of Neurosurgery 117: 629-637. (PMID: 22746378)

  9. Seminerio, M. J., Robson, M. J., McCurdy, C. R. and Matsumoto, R. R. (2012) Sigma receptor ligands attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1 beta mRNAexpression in the hypothalamus. European Journal of Pharmacology 691: 103-109. (PMID: 22820108)

  10. James, M. L., Shen, B., Zavaleta, C. L., Nielsen, C. H., Mesangeau, C., Vupalla, P. K., Chan, C., Avery, B. A., Fishback, J. A., Matsumoto, R. R., Gambhir, S. S., McCurdy, C. R. and Chin, F. T. (2012) A new positron emission tomography (PET) radioligand for imaging sigma-1 receptors in living subjects. Journal of Medicinal Chemistry 55: 8272-8282. (PMID: 22853801)

  11. Fishback, J. A., Rosen, A., Bhat, R., McCurdy, C. R. and Matsumoto, R. R. (2012) A 96-well filtration method for radioligand binding analysis of sigma receptor ligands. Journal of Pharmaceutical and Biomedical Analysis 71: 157-161. (PMID: 22910107)

  12. Kaushal, N., Seminerio, M. J., Robson, M. J., McCurdy, C. R. and Matsumoto, R. R. (2013) Pharmacological evaluation of SN79, a sigma receptor ligand, against methamphetamine-induced neurotoxicity in vivo. European Neuropsychopharmacology 23: 960-971. (PMID: 22921523)

  13. Seminerio, M. J., Hansen, R., Kaushal, N., Zhang, H. T., McCurdy, C. R. and Matsumoto, R. R. (2013) The evaluation of AZ66, an optimized sigma receptor ligand, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. International Journal of Neuropsychopharmacology 16: 1033-1044. (PMID: 22932447)

  14. Behensky, A. A., Cortes-Salva, M., Seminerio, M. J., Matsumoto, R. R., Antilla, J. C. and Cuevas, J. (2013) In vitro evaluation of guanidine analogues as sigma receptor ligands for potential anti-stroke therapeutics. Journal of Pharmacology and Experimental Therapeutics 344: 155-166. (PMID: 23065135)

  15. Robson, M. J., Turner, R. C., Naser, Z. J., McCurdy, C. R., Huber, J. D. and Matsumoto, R. R. (2013) Methamphetamine-induced microglial activation and cytokine upregulation: antagonism by a sigma receptor ligand. Experimental Neurology 247: 134-142. (PMID: 23631864)

  16. Robson, M. J., Seminerio, M. J., McCurdy, C. R., Coop, A. and Matsumoto, R. R. (2013) σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacological Reports 65: 343-349. (PMID: 23744418)

  17. Bhat, R., Fishback, J. A., Matsumoto, R. R., Poupaert, J. H. and McCurdy, C. R. (2013) Structure activity relationship of benzo[d]thiazol-2(3H)one based sigma receptor ligands. Bioorganic Medicinal Chemistry Letters 23: 5011-5013. (PMID: 23867168)

  18. Stavitskaya, L., Seminerio, M. J., Healy, J. R., Noorbakhsh, B., Matsumoto, R. R. and Coop, A. (2013) Effect of ring-constrained phenylpropyloxyethylamines on sigma receptors. Bioorganic and Medicinal Chemistry 21: 4923-4927. (PMID: 2389661)

  19. Healy, J. R., Bezawada, P., Shim, J., Jones, J. W., Kane, M. A., MacKerell, A. D. Jr., Coop, A. and Matsumoto, R. R. (2013) Synthesis, modeling and pharmacological evaluation of UMB 425, a mixed mu agonist/delta antagonist opioid analgesic with reduced tolerance liabilities. ACS Chemical Neuroscience 4: 1256-1266. (PMID: 23713721)

  20. Turner, R. C., Naser, Z. J., Logsdon, A. F., DiPasquale, K., Jackson, G. J., Robson, M. J., Gettens, R. T. T., Matsumoto, R. R., Huber, J. D. and Rosen, C. L. (2013) Modeling clinically relevant blast parameters based on scaling principles produces functional and histological deficits in rats. Experimental Neurology 248: 520-529. (PMID: 23876514)

  21. Motel, W. C., Healy, J. R., Viard, E., Pouw, B., Martin, K. E., Matsumoto, R. R. and Coop, A. (2013) Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands. Bioorganic Medicinal Chemistry Letters 23: 6920-6922. (PMID: 24211020)

  22. Kaushal, N., Robson, M. J., Rosen, A., McCurdy, C. R. and Matsumoto, R. R. (2014) Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazine-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro. European Journal of Pharmacology 724: 193-203. (PMID: 24380829)

  23. Turner, R. C., VanGilder, R. L., Naser, Z. J., Lucke-Wold, B. P., Bailes, J. E., Matsumoto, R. R., Huber, J. D., Rosen, C. L. (2014) Elucidating the severity of preclinical traumatic brain injury models: A role for functional assessment? Neurosurgery 74: 382-394. (PMID: 24448183)

  24. Matsumoto, R. R., Nguyen, L., Kaushal, N. and Robson, M. J. (2014) Sigma receptors as potential therapeutic targets to mitigate psychostimulant effects. Advances in Pharmacology 69: 323-386. (PMID: 24484982)

  25. Robson, M. J., Turner, R. C., Naser, Z. J., McCurdy, C. R., O’Callaghan, J. P., Huber, J. D. and Matsumoto, R. R. (2014) SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Experimental Neurology 254C: 180-189. (PMID: 24508558)

  26. Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. and Matsumoto, R. R. (2014) Dextromethorphan produces antidepressant-like effects through sigma-1 receptors. PLOS ONE 9: e89985. (PMID: 24587167)

  27. Matsumoto, R. R., Seminerio, M. J., Turner, R., Robson, M. J., Nguyen, L., Miller, D. B. and O’Callaghan, J. P. (2014) Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia. Pharmacology and Therapeutics 144: 28-40. (PMID: 24836729)

  28. Healy, J. R., Tonkin, J. L., Kamarec, S. R., Saludes, M. A., Ibrahim, S. Y., Matsumoto, R. R. and Wimsatt, J. H. (2014) Evaluation of an improved sustained-release buprenorphine formulation for use in mice. American Journal of Veterinary Research 75: 619-625. (PMID: 24959727)

  29. Nguyen, L., Kaushal, N., Robson, M. J. and Matsumoto, R. R. (2014) Sigma receptors as potential therapeutic targets for neuroprotection. European Journal of Pharmacology 743: 42-47. (PMID: 25261035)
  30. Logsdon, A. F., Turner, R. C., Lucke-Wold, B. P., Robson, M. J., Naser, Z. J., Smith, K. E., Matsumoto, R. R., Huber, J. D. and Rosen, C. L. (2014) Altering endoplasmic reticulum stress in a model of blast-induced traumatic brain injury controls cellular fate and ameliorates neuropsychiatric symptoms. Frontiers in Cellular Neuroscience 8: 420. (PMID: 25540611)

  31. Nguyen, L. and Matsumoto, R. R. (2015) Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Behavioral Brain Research 295: 26-34. (PMID: 25804358)

  32. Nguyen, L., Weaver, C. B., Cramer, K. J., Pollard, S. E., Marshalek, P. J. and Matsumoto, R. R. (2015) Off-label use of transmucosal ketamine as a rapid acting antidepressant: a retrospective chart review. Neuropsychiatric Disease and Treatment 11: 2667-2673. (PMID: 26508862)

  33. Nguyen, L., Mookerjee, S. A., Lucke-Wold, B. P., Cavendish, J. Z., Robson, M. J., Scandinaro, A. L. and Matsumoto, R. R. (2015) Role of sigma-1 receptors in neurodegenerative diseases. Journal of Pharmacological Sciences 127: 17-29. (PMID: 25704014)

  34. Lucke-Wold, B. P., Nguyen, L., Turner, R. C., Logsdon, A. F., Chen, Y.-W., Smith, K. E., Huber, J. D., Matsumoto, R., Rosen, C. L., Tucker, E. S. and Richter, E. (2015) Traumatic brain injury and epilepsy: underlying mechanisms leading to seizure. Seizure 33: 13-23. (PMID: 26519659)

  35. Nguyen, L., Lucke-Wold, B. P., Thomas, K., Scandinaro, A. L. and Matsumoto, R. R. (2016) Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacology and Therapeutics 159: 1-22. (PMID: 26826604)

  36. Logsdon, A. F., Lucke-Wold, B. P., Nguyen, L., Matsumoto, R. R., Turner, R. C., Rosen, C. L. and Huber, J. D. (2016) Salubrinal reduces oxidative stress, neuroinflammation and impulsive-like behavior in a rodent model of traumatic brain injury. Brain Research 1643: 140-151. (PMID: 27131989)                                                                                         
  37. Nguyen, L., Lucke-Wold, B. P., Logsdon, A. F., Scandinaro, A. L., Huber, J. D. and Matsumoto, R. R. (2016) Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice. NeuroReports 27: 1004-1011. (PMID: 27580401)                                                                                                   
  38. Taylor, C. P., Traynelis, S. F., Siffert, J., Pope, L. E. and Matsumoto, R. R. (2016) Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta) clinical use. Pharmacology and Therapeutics 164: 170-182. (PMID: 27139517)

Academy of Managed Care Pharmacy
American Association of Colleges of Pharmacy
American Society of Pharmacology and Experimental Therapeutics
California Society of Health Systems Pharmacists
College on Problems of Drug Dependence
Society for Neuroscience

Last Updated: 11/11/16